Phase 2 trial of TU2218, TGFβ-RI, and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with biliary tract cancer and head and neck cancer.

Authors: Do-Youn Oh, Sung-Bae Kim, Jin Won Kim, Hun-taek Kim, Marya F. Chaney

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps2691

Source: Full article

---

Abstract

TPS2691